Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEGEND: Glimepiride + Metformin in T2DM
NCT01699932Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2012
- Primary completion
- Apr 2014
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of glimepiride and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Change in HbA1c at 24 weeks. Started Sep 2012; status: completed.
02
Drugs
glimepirideliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01699932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01699932.